Company: HURA
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0000950170-25-047921
Chunk: 278

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-03-31
Form: 10-K
Item: Item 1B
Chunk 278
---
 liabilities assumed plus merger transaction costs
         
        $
        (5,476,575
        )
       
       Accounting treatment on the Contingent Value Rights “CVR” agreementBased on management’s analysis, the CVRs were identified as freestanding financial instruments and determined to be indexed to Kintara’s own stock, as they are to be settled in Kintara Common Stock. Further, the CVR financial instruments are not mandatorily redeemable as the instruments do not require Kintara to redeem them for cash or other assets at a fixed or determinable date, or upon an event that is certain to occur and the CVRs do not represent an unconditional obligation requiring Kintara to redeem the instruments. The CVRs do not represent outstanding shares of Kintara Common Stock, and the CVRs do not obligate Kintara to buy back some or all of its shares. As such, the CVRs are not precluded from being classified within equity. Given the CVRs are initially being recorded 

F-17

TUHURA BIOSCIENSES, INC AND SUBSIDIARIESNotes to the consolidated financial statementsFor the years ended December 31, 2024, and 2023  

within Equity, if the CVR Milestone were to be achieved, the Company would issue additional Common Stock, thereby resulting in a reclass of the CVRs from Additional paid-in capital—CVRs to Common Stock and Additional paid-in capital. As a result, the accounting for the CVR is determined to have zero net effect on total equity within the consolidated balance sheet as of December 31, 2024. 

Note 7—Other current assetsOther current assets consist of the following as of December 31, 2024, and 2023: 

        December 31,

        December 31,

        2024

        2023

        Employee Retention Tax Credit
         
        $
        214,699

        $
        334,443

        NIH Grant Receivable

        222,702

        -

        Clinical trial deposit

        204,955

        -

        Other current assets

        316,352

        159,326

        $
        958,708

        $
        493,769

Note 8—Property and equipment, netProperty and equipment, net consists of the following as of December 31, 2024, and 2023: 

        December